TGFB1 and neoplasm: Based on this consideration, the combinatorial activity of TGFβ- and PD1-neutralizing antibodies was also assessed in mice inoculated with MC38, an immune-inflamed tumor type with heterogeneous responsiveness to immunotherapies.